Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.
Andreas Schneeweiss
Consultant or Advisory Role - Roche
Honoraria - Roche
Marcus Schmidt
Consultant or Advisory Role - Roche
Stock Ownership - Roche
Honoraria - Roche
Frank Gerhard Foerster
No relevant relationships to disclose
Matthias Geberth
No relevant relationships to disclose
Hans Tesch
Consultant or Advisory Role - Roche
Honoraria - Roche
Peter Klare
No relevant relationships to disclose
Claudia Schumacher
No relevant relationships to disclose
Wiebke Hollburg
No relevant relationships to disclose
Ulrike Soeling
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Andreas Kutscheidt
No relevant relationships to disclose
Sherko Kümmel
Consultant or Advisory Role - Roche
Research Funding - Roche